Medicenna Reports Promising Fiscal 2025 Results and Advances in Immunotherapy Programs

Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an update.

Medicenna Therapeutics Corp reported its fiscal year 2025 financial results and operational highlights, emphasizing the progress of its MDNA11 and MDNA113 programs. The MDNA11 Phase 1/2 clinical trial is on track for data readouts, showing promising anti-tumor activity in difficult-to-treat solid tumors, with some patients achieving complete remission. The company plans to advance MDNA113 to non-human primate studies and aims to solidify its Phase 2b development strategy for MDNA11 by the end of the year, potentially impacting its market positioning in the immunotherapy sector.

The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$3.75 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.

Spark’s Take on TSE:MDNA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.

Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.

To see Spark’s full report on TSE:MDNA stock, click here.

More about Medicenna Therapeutics Corp

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer, autoimmune, and inflammatory diseases.

Average Trading Volume: 31,147

Technical Sentiment Signal: Sell

Current Market Cap: C$62.52M

Learn more about MDNA stock on TipRanks’ Stock Analysis page.